Phibro Animal Health (NASDAQ:PAHC) Shares Cross Below 200 Day Moving Average - Here's What Happened

Key Points

• Phibro Animal Health shares fell below their 200-day moving average, trading as low as $33.83 versus the $42.82 average, and last changing hands at $34.06.
• Analyst sentiment has weakened: Citigroup reduced its price target to $44 and several firms downgraded the stock. The consensus rating is “Hold”, with an average target price of $42.50.
• The company declared a quarterly dividend of $0.12 per share, equivalent to $0.48 annually and a 1.4% yield; institutional investors own 99.34% of the outstanding shares.

Phibro Animal Health Corporation (NASDAQ:PAHC - Get Free Report) shares passed below its two hundred day moving average during trading on Thursday . The stock has a two hundred day moving average of $42.82 and traded as low as $33.83. Phibro Animal Health shares last traded at $34.06, with a volume of 128,887 shares.

Wall Street Analyst Weigh In

A number of research analysts recently weighed in on the stock. Citigroup cut their target price on shares of Phibro Animal Health from $62.00 to $44.00 and set a "neutral" rating for the company in a report on Thursday, May 14th. Zacks Research downgraded shares of Phibro Animal Health from a "strong-buy" rating to a "hold" rating in a research note on Thursday, May 21st. Wall Street Zen cut shares of Phibro Animal Health from a "strong-buy" rating to a "buy" rating in a research note on Saturday, May 9th. Finally, Weiss Ratings downgraded shares of Phibro Animal Health from a "buy (b-)" rating to a "hold (c+)" rating in a report on Monday, June 15th. One equities research analyst has rated the stock with a Buy rating, three have issued a Hold rating and one has given a Sell rating to the stock. According to data from MarketBeat.com, Phibro Animal Health has an average rating of "Hold" and an average target price of $42.50.

Phibro Animal Health Stock Performance

The stock has a market capitalization of $1.38 billion, a PE ratio of 14.62, a PEG ratio of 0.48 and a beta of 0.46. The business's 50 day moving average is $33.31 and its 200 day moving average is $42.82. The company has a current ratio of 3.17, a quick ratio of 1.26 and a debt-to-equity ratio of 1.97.

Phibro Animal Health Dividend Announcement

The firm also recently announced a quarterly dividend, which will be paid on Wednesday, September 23rd. Stockholders of record on Wednesday, September 2nd will be paid a dividend of $0.12 per share. The ex-dividend date of this dividend is Wednesday, September 2nd. This represents a $0.48 dividend on an annualized basis and a dividend yield of 1.4%. Phibro Animal Health's dividend payout ratio is currently 20.60%.

Hedge Funds Weigh In On Phibro Animal Health

A number of large investors have recently bought and sold shares of PAHC. 1620 Investment Advisors Inc. increased its stake in Phibro Animal Health by 77.4% in the fourth quarter. 1620 Investment Advisors Inc. now owns 676 shares of the company's stock worth $25,000 after purchasing an additional 295 shares during the period. Farther Finance Advisors LLC boosted its stake in shares of Phibro Animal Health by 113.2% during the fourth quarter. Farther Finance Advisors LLC now owns 727 shares of the company's stock valued at $27,000 after purchasing an additional 386 shares during the period. KBC Group NV bought a new position in shares of Phibro Animal Health in the first quarter worth about $29,000. Rothschild Investment LLC grew its holdings in shares of Phibro Animal Health by 2,500.0% in the fourth quarter. Rothschild Investment LLC now owns 1,040 shares of the company's stock worth $39,000 after purchasing an additional 1,000 shares during the last quarter. Finally, iSAM Funds UK Ltd purchased a new position in Phibro Animal Health in the 3rd quarter worth about $61,000. Hedge funds and other institutional investors own 99.34% of the company's stock.

Phibro Animal Health Company Profile

Phibro Animal Health Corporation NASDAQ: PAHC is a diversified global animal health and mineral nutrition company headquartered in Teaneck, New Jersey. The company develops, manufactures and markets a broad range of pharmaceutical, mineral nutrition and performance products designed to support the health and productivity of livestock, companion animals and aquaculture species. Phibro's portfolio includes vaccines, anti-infective therapies, coccidiostats, disinfectants, premix minerals and specialty feed additives aimed at enhancing growth, immunity and overall animal well-being.

The company operates through three principal business segments: Animal Health, Mineral Nutrition and Performance Products.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.

Continue following MarketBeat

Add MarketBeat as your preferred source on Google to see our latest stories in your feed.

Add As Preferred Source